GlassScriptPhysician profile
Jerry Lipinski
NPI 1639638802
$13,243.46
in general payments reported to CMS, 2019-2025
10 companies · $11K in 2025
The $11K reported for 2025 was more than what 99% of providers received nationally.
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $317 · 2023: $151 · 2024: $2,104 · 2025: $11K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Grant: $7,000 · Travel and Lodging: $3,732 · Food and Beverage: $2,095 · Education: $99.44.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Grant | $7,000.00 |
| Travel and Lodging | $3,732.36 |
| Food and Beverage | $2,094.99 |
| Education | $99.44 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medtronic, INC. | $8,239.70 | 2025 | Corevalve Evolut R |
| Edwards Lifesciences Corporation | $2,052.34 | 2025 | Sapien 3 Ultra Resilia |
| Abbott Laboratories | $1,910.13 | 2023-2024 | Optis, Ensite, Aveir |
| Boston Scientific Corporation | $194.94 | 2024-2025 | Watchman Flx, General - Vascular Access |
| Astellas Pharma US INC | $186.98 | 2022 | |
| Abiomed | $186.98 | 2025 | |
| Heartflow, INC. | $172.80 | 2024 | |
| Penumbra, INC. | $143.00 | 2025 | Indigo System |
| Sanofi-Aventis U.S. LLC | $129.69 | 2022 | |
| E.R. Squibb & Sons, L.L.C. | $26.90 | 2023 | Camzyos |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jerry Lipinski listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.